Filter articles using the following links

GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update

GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ® Gene Therapy

GenSight Biologics announces a financing for an amount of c. €1.5 million from existing investors

GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation

GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France

GenSight Biologics announces a financing for an amount of c. €2.8 million from existing investors

GenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ®

GenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update

GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024

GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates